Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT019580...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022531/
https://www.ncbi.nlm.nih.gov/pubmed/29654415
http://dx.doi.org/10.1007/s10549-018-4769-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022531/
https://www.ncbi.nlm.nih.gov/pubmed/29654415
http://dx.doi.org/10.1007/s10549-018-4769-z

Ejemplares similares